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Abstract 
The ravaging consequences of Malaria in Sub-Saharan Africa (SSA) have been a subject of serious concern to every 
stakeholder. Literature and anecdotal evidence shows that around 60% of Nigerians seek fever treatment from Patent 
Medicine Vendors (PMVs) despite the limited formal dispensing knowledge most possess. This study attempts to 
establish a base line of knowledge, attitude and practices of Malaria control among PMVs in Gombe Metropolis, North 
Eastern Nigeria. The study was a descriptive cross sectional survey based on structured questionnaires used to collect 
relevant information from 109 PMVs selected by purposive sampling technique. The result show that 85.3% of the 
participants in this study correctly identified fever or high body temperature as the common sign of uncomplicated (UC) 
Malaria, while 70.6% recognized convulsion as one of the main symptoms of severe Malaria. Furthermore, 86.2% of the 
PMVs also knew that sleeping inside treated nets constitute one of the best ways to prevent Malaria. In the same vein, 
awareness of change in Malaria treatment policy from monotherapy to Artemisinin based combination therapy (ACT) 
was high (73.3%) among them. However, those PMVs that had ever undergone some degree of drug dispensing training 
exhibited a significantly higher level of awareness of change in malaria treatment policy (X2 =17.903, P = 0.000). 
Although 85.3% of PMVs frequently recommend Arthemeter Lumefantrine (AL) as treatment of uncomplicated Malaria, 
only 39.4% of the participants would refer severe malaria cases. Even though most Malaria control awareness and 
practice variables were found to be fairly good among the participants, it is clear from the study that there is the need 
for enhanced training, monitoring and supervision by the relevant authorities so as to fully harness the vast potential 
in PMVs.  
Keywords:  Malaria; PMVs; Awareness; Diagnosis; Treatment; Prevention 
1. Introduction
According to the WHO world Malaria report, an estimated 212 million cases of malaria occur worldwide and 90% 
malaria cases were in the WHO African Region, with 29% being contributed by Nigeria alone [1].  Global malaria 
mortality estimate was 429, 000 of which 92% occurred in the WHO African Region, with Nigeria accounting for 26% 
of the death [1, 2]. Despite some modest achievement recorded in the fight against Malaria 303, 000 malaria deaths 
were estimated to have occurred in children aged under 5 years, equivalent to 70% of the global total deaths - malaria 
remains a major killer of children, and is estimated to take the life of a child every 2 minutes [1, 2]. While the healthcare 
system in the country does present limitations around access to malaria and other communicable diseases, community 
access to PMVs and essential health-care products are core elements of patient-centred health-care systems which the 
GSC Biological and Pharmaceutical Sciences, 2021, 14(03), 113–121 
114 
community rely upon especially in places without access to formal health care [2, 3]. The disturbing epidemiological 
pattern of communicable diseases has resulted in the conceptualization and deployment of so many control efforts 
including the Public Private Partnership (PPP) model, especially in the African region where communities are worst hit 
[4,5].  
The involvement of Patent Medicine Vendors (PMVs) in the delivery of some form of primary health care and malaria 
control in developing countries has for some time now been a subject of robust debate and active research [3, 6, 7, 8, 9, 
10, 11]. The growing body of evidence points more to the merits than demerits of PMVs involvement in the promotion 
of access to medicines especially in Low and Middle income countries [3,6,12]. The introduction of global initiatives 
such as the Affordable Medicines Facility for malaria (AMFm) was viewed as an avenue to explore ways in which PMVs 
can be utilized as vehicle to help expand coverage for essential health services  delivery [3,6,13,14]. However, the 
apprehension on the use of this medium is around the lack of existing veritable machinery for effective monitoring and 
quality assurance, and lack of capacity for service delivery considering the fact that the licensing requirement for PMVs 
has no minimum academic benchmark [15]. This is against the back drop of preponderant cases of fake drugs 
dispensation by Patent Medicine Shops, lack of adherence to the Pharmaceutical Council of Nigeria stipulated rules of 
practice for PMVs, rampant cases of inappropriate dispensing and irrational use or dosing of drugs sold by PMVs [2, 16, 
17, 18].  The regulation of malaria drug in Nigeria is complex, with several key stakeholders involved. The National 
Malaria Control Program (NMCP), an organ under the Federal Ministry of Health (FMOH) regulates the scientific basis 
for recommending appropriate treatment [19]. The National Agency for Food and Drugs Administration and Control 
(NAFDAC) is charged with testing, approval, registration as well as inspection of drug manufacturing premises and 
regulations of advertisement of pharmaceutical in country [2, 17,20].  
Despite these concerns PMVs accounts for 39% source of malaria treatment in Nigeria [17]. Most people do not obtain 
appropriate treatment for malaria, and depend on informal private providers for anti-malarial drugs, mainly through 
patent medicine vendors (PMVs). The picture is similar across sub-Saharan Africa where PMVs are widely used source 
of drugs for malaria treatment across the continent [3,6,21]. The Nigeria Malaria Indicator Survey, 2010, reported 
higher estimate (57%) of people in Nigeria that would first call at a PMV store to seek treatment [22].  It has been widely 
reported that there are several brands of Artemisinin-based combination therapies (ACTs) first-and second-line drug 
for malaria treatment as recommended by the national treatment guideline in the Nigerian market that are now 
purchased over the counter [13, 17,20].  
In Nigerian context, PMVs are major providers of health care services and most PMVs in Nigeria belong to local affiliates 
of the National Association of Patent and Proprietary Medicine Dealers (NAPPMED) [23]. As frontline health workers, 
PMVs perform multiple tasks, including consultation, counseling, treatment and referral of sick clients in medically 
underserved communities. The operations of PMVs is licensed by the Pharmacy Council of Nigeria to sell patent 
medicine and in possession of patent and proprietary medicine vendors' license in the form B or C as contained in the 
Pharmacy Law of Nigeria [3,7]. Under this arrangement PMVs are permitted to sell pre‐packaged, over‐the‐counter 
(OTC) medicines only, and in addition such licensees are required to be at least 21 years of age and required to complete 
an apprenticeship training with a more senior PMV [3,10,20,24]. To a certain degree, there is almost nonexistence of 
evidence of completion of apprenticeship documented within the system. Other PMVs are retired health workers such 
as pharmacy assistants, nurses, community health workers, and civil servants. To have further insight into the role 
played by PMVs in the delivery of healthcare in Gombe metropolis the study explores the knowledge, awareness and 
practice of malaria prevention and management among the PMVs within the area.  
2. Material and methods 
2.1.  Study Setting 
Participants were drawn from Gombe metropolis, the state capital of Gombe within the North eastern region of the 
country. The state borders with Borno, Yobe, Adamawa, Taraba, and Bauchi states, with a land area of 20, 265 SqKm 
and population of 3,256,962 and around 11.4% are resident within the state capital [25]. The climatic conditions are 
characterized by a dry season lasting from October to April, while the rainy season lasts between May and September. 
Climate change, flooding, deforestation, waste management, and mining are emerging health and environmental 
challenges in the region. 
2.2. Study Design and Study Population 
An exploratory cross sectional descriptive survey was adopted to measure the participants’ knowledge, awareness and 
practice and any association of their characteristics with malaria drug dispensing. The study population comprises 
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Patent Medicine Vendors (PMVs) registered with the state chapter of the National Association of Patent and Proprietary 
Medicine Dealers (NAPPMED) with physical stores or “chemists” within Gombe Metropolis.  
As at the time of the data collection a total of 137 PMVs were officially listed on NAPPMED register. Though all (137) 
were targeted to take part in the study, only 109 of them eventually responded to the questionnaires. The rest either 
declined or were absent at the times of the data collection.  
2.3. Data Collection Instrument and Data Collection 
A structured questionnaire comprising 28 items was developed and validated prior to the data collection. The developed 
questionnaire was first tested among 15 participants outside the sampling area within the metropolis and based on the 
information generated further adjustments were done on the questionnaire to make it more comprehensible and 
adopted for the main study. The questionnaire was divided into sections that seek information around participants’ 
socio-demographic data, knowledge of Malaria diagnosis and prevention, practice around Malaria treatment and 
training/awareness among the PMVs. The data for this work was collected between the months of June and September, 
2014; during the monthly coordination meetings of the association (NAPPMED).  
2.4. Ethical Considerations 
The data collection was done in conjunction with the PMVs association (NAPPMED) officials who were made to 
understand the significance of the study. That notwithstanding, none of the participants was compelled to participate 
in the survey such that all was done in compliance with the Helsinki declaration. 
2.5. Data Analysis 
The data collected was analyzed using Statistical Package for Social Sciences (SPSS) Window Version 16.0 (Chicago, 
SPSS Inc.) Simple frequency tables, bar charts and cross tabulations were generated and relationships between 
variables were tested using chi square and Odd Ratio (OR). Associations were considered significant at P-values < 0.05. 
3. Results  
Table 1 presents socio-demographic characteristics of the participants. The data analyzed show that the participants 
mean age was 30.41±9.26 years and 88% of the participants age lie between 17 and 40 depicting an active population 
engaged in the vending trade within the study area. High proportion of the participants (83.2%) were males which 
shows an under representation of females working in the industry. In addition, 54.1% of the participants were educated 
only up to secondary school level, leaving 40.4% as having tertiary level education. 
Table 1 Socio-demographic data 
Variable                                                                               Frequency Percentage (%) Mean±SD 
Age group    
<=20                                                                                                    23 23  
 21-30                                                                                                     33 33 30.41±9.2585 
 31-40                                                                                                       32 32  
>40                                                                                                         12 12  
Sex     
 Male                                                                                              89 83.2  
 Female                                                                                                18 16.8 ditto 
Level of Education    
 No education                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1 0.9
Primary                                                                                                                                                                                                                                                                                                                                           5 4.6 ditto 
Secondary                                                                                              59 54.1  
Tertiary                                                                                                44 40.4  
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Table 2 present participants awareness of malaria treatment as enshrined in the national antimalarial treatment 
guidelines and participants training engagement to upskill their knowledge around the update contained in the 
guidelines. From the result, 73.3% said they are aware of the treatment changes introduced in the updated guidelines 
from monotherapy (i.e. Chloroquine, SP) to Artemisinin-based Combination Therapy (ACT) such as Arthemeter 
Lumefantrine (AL) etc. In addition, only 56.6% of the participants acknowledge ever undergone formal training with 
malaria component, demonstrating poor knowledge among the participant around the use of national antimalarial 
treatment guidelines. The table (2) also present the participants’ knowledge of common signs and symptoms of malaria 
for uncomplicated and severe malaria. For uncomplicated malaria, 85.30% of the respondents identified fever or 
elevated body temperature as the main sign malaria. Bodily pain was the least symptom (0.9%) the participants 
identified as sign of uncomplicated malaria followed by vomiting (2.8%). When asked of the symptoms of severe malaria 
70% participants indicated convulsion, followed by fever/elevated body temperature (21.1%). Other signs and 
symptoms asked were less likely to be considered when attending to clients.  
Table 2 Awareness and signs and symptoms of malaria. 
Variable                                                       Frequency Percentage  
Awareness of change in Malaria treatment policy    
   Yes                                                                                    74 73.3 
    No                                                                                    27 26.7 
  Total                                                                             101 100 
Ever undergone any health care training on Malaria   
   Yes                                                                                   60 56.6 
    No                                                                                      46 43.4 
  Total                                                                                106 100 
Uncomplicated Malaria (n=109)   
  Headache 7 6.4% 
  Tiredness/Joint or muscle pains 5 4.6% 
  Loss of appetite 7 6.4% 
  Body pain/aches 1 0.9% 
  Vomiting  3 2.8% 
  Rigors/shivering 4 3.7% 
  Feeling cold/chills  8 7.3% 
  Fever/high body temperature 93 85.3% 
Severe Malaria (n=109)   
   Jaundice or yellowing of the eyes 2 1.8% 
   Difficulty in breathing 4 3.7% 
   Severe pallor 4 3.7% 
   Inability to drink or breastfeed 3 2.8% 
   Unconsciousness 4 3.7% 
   Lethargy/Prostration/Generalized body weakness 8 7.3% 
   Convulsion 77 70.6% 
   Fever/Elevated temperatures 23 21.1% 
Table 3 shows PMVs’ exposure to training on malaria and awareness of the new national malaria treatment policy. 
Majority of the participants (89.5%) that demonstrated awareness of the new treatment policy also indicated having 
undergone training on malaria treatment based on the new policy. Hence, there were higher (about 8 times) odds (OR 
= 8.095, 95% CI = CI = 2.8490 – 23.0024) of awareness of the new malaria treatment policy among those exposed to training 
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than those who were not. This relationship between participants awareness of the new malaria treatment policy and 
having undergone training on malaria, was statistically significant (X2 =17.903, df = 1, p = 0.000).  
Table 3 PMVs’ training and awareness of new antimalarial treatment policy and guideline. 
Ever undergone any 
training on Malaria  
 Awareness of new malaria treatment policy and prevention  
Yes (%)                No (%)                Total (%) 
Yes (%)                                                              51 (89.5)          6 (10.5)                57 (100.0) 
No (%)                                   21 (51.2)              20 (48.8)              41 (100.0) 
Total (%)                                   72 (73.5)             26 (26.5)              98 (100.0) 
X2 =17.903,   df = 1, P = 0. 000, OR=8.095    CI = 2.8490 – 23.0024 
Table 4 shows the anti-malarial drugs (AMDs) commonly dispensed for the treatement of uncomplicated malaria by the 
participants.  Arthemeter Lumefantrine (AL) (85.30%) was the predominant drug dispensed and was closely followed 
by Sulphadoxine Pyrimethamine (SP) (84.40%) and Artesunate Monotherapy (29.4%) respectively. In case of severe 
malaria treatment, 39.40% indicated their preferred treatment regime would be to refer the patients to health care 
facility (hospital) for further management. An appreciable proportion (39.4%) of the PMVs would prescribe Artemisinin 
Lumefantrine (AL). This was followed by Sulphadoxine Pyrimethamine (SP) where 34.9% said they will consider it as 
treatment regime for severe malaria.  
Table 4 Drugs sold or actions taken by PMVs for malaria Treatment (n=109). 
Uncomplicated malaria  Frequency 
  DHA Piperaquine 3.7% 
  Ateminsinin monotherapy 0.9% 
  Halofantrine 1.8% 
  Artemisinin Lumefantrine (AL) 85.3% 
  Artesunate monotherapy 29.4% 
  Artesunate Amodiaquine (AA) 1.8% 
  Sulphadoxine Pyrimethamine (SP) 84.4% 
  Chloroquine (CQ) 2.8% 
Severe malaria  
  Refer to hospital 39.4% 
  Halofantrine 0.9% 
  Artemisinin Lumefantrine (AL) 39.4% 
  Artesunate monotherapy 11.9% 
  Artesunate Amodiaquine (AA) 0.9% 
  Sulphadoxine Pyrimethamine (SP) 34.9% 
  Chloroquine (CQ) 0.9% 
  Quinine 1.8% 
   Others 0.9% 
Malaria preventative approach 
Sleep under insecticide treated nets 
Use of insecticide spray/IRS 
Improved environmental sanitations 
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In addition, malaria preventative approach as part of service offered to patients prior to dispensing malaria drugs was 
assessed. Based on the question asked, 86.2% of participants identified sleeping inside long lasting insecticidal nets 
(LLINs) or insecticide treated nets (ITNs) as the best way of preventing Malaria. Use of insecticide and other means (i.e. 
traditional methods) were the least favoured malaria preventive measures considered among the participants. 
 
Figure 1 Best ways to prevent Malaria (n=109) 
4. Discussion    
Participants socio-demographic characteristics is typical of an active sub-population with a mean age of 30.41±9.2585 
years with male dominance of 83.2%  and more than a half (54.1%) of the PMVs were educated only up to secondary 
school level. This outcome affirms the fears expressed by many, that the lack of a good benchmark for enrollment into 
the trade might compromise quality of drug vending and public health [15,24,26,27].  A vast majority of the respondents 
said their diagnosis of malaria is based on symptoms of which body ache, high temperature, loss of appetite, convulsion 
etc. are the most frequent symptoms they use to base their conclusion. Overwhelming majority (85.3%) of the PMVs 
said fever or high body temperature is the main sign of uncomplicated (UC) malaria and convulsion as the major sign 
(70.6%) of severe malaria. This findings corroborate the conclusion drawn by Goodman et al and Beyeler & Sieverding 
where high temperature (fever), convulsion, loss of appetite are among the most common symptoms identified PMVs 
[3,7]. 
The study revealed Artemisinin Lumefantrine as the most likely malaria treatment to be dispensed among the 
participants when treating either uncomplicated or severe malaria.  Only 39.4% of the participants will consider referral 
of patients manifesting signs of severe malaria to health facilities (hospital/clinics) for further management. The study 
also highlighted on the need to enhance training and awareness around  the national malaria treatment guidelines to 
help strengthen capacity among the PMVs considering the vital role they play towards the delivery of primary 
healthcare especially in areas with limited access to health facilities. While the present study did not assess the content 
and accuracy of information provided to customers at the point of dispensing malaria treatment, previous studies have 
demonstrated that PMVs vary widely in the amount, accuracy and quality of information they are likely to provide to 
their clients [3,24,26,28]. There is also the need to apply caution on the role played by PMVs in the delivery of basic 
health services as it relates to quality assurance.  Previous studies conducted in LMICs including Nigeria has 
demonstrated poor capacity of PMVs in preventive care, diagnosis and proper dispensing of drugs as well as their 
engagement in unlicensed practices, trade in substandard and counterfeit antimalarial drugs which have contributed 
significantly to high burden of malaria and comorbidities in the country [2,20,26,29,30,31]. There is no doubt that 
addressing this gap will result in fewer hospitalizations and death due to malaria infection in the country. 
In addition to dispensing antimalarial drugs, the participants said they provide other advise around malaria prevention 
of which 86.2% said they encourage sleeping inside insecticide treated nets (ITNs) to prevent malaria infection. This 
further demonstrates the potential in PMVs for the delivery of some form of Primary Health care interventions 
[3,7,8,21]. The anti-malarial drugs (AMDs) commonly dispensed for UC Malaria by the participants were mostly 
Arthemeter Lumefantrine (AL) (85.30%), Sulphadoxine Pyrimethamine (SP) (84.4%) and to minimal extent Artesunate 
Monotherapy (29.4%). This apparent high rate of dispensing of the nationally recommended ACT/AL as first line AMD 
may not be unconnected with the continuous awareness creation around ACT subsidy interventions in place by 
nongovernment organizations (NGOs) that include Society for Family Health (SFH) in the study area. However, what is 
still considered worrisome is 29.40% of the PMVs who took part in this study affirmed dispensing monotherapies as 
malaria treatment which leaves gap that still needs to be filled by continuous targeted behavior change communication 
(BCC) activities. This additionally, re-echoes the call for improvement in performance of PMVs through training 
especially in Sub-saharan Africa and other LMICs countries [3,30,32,33,34] and our findings show that only 39.40% of 
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the PMVs in the study area indicated their willingness to always refer clients with symptoms of severe malaria to health 
facilities for further prognosis cum treatment. Others (39.4%) said they would prescribe AL as first line of treatment 
followed by those who would dispense SP. This findings is in tandem with other studies conducted in the country where 
other monotherapies that include SP, quinine etc. were widely prescribed for malaria treatment [11,35]. In these 
scenarios, drug promotion and clients’ demand could have been a key factor on the frequency of each drug being sold 
to the public. 
A good  proportion (73.3%) of the PMVs were found to be aware of changes made in the malaria treatment policy from 
mono-therapy (such as Chloroquine, SP etc) to Artemisinin-based Combination Therapy (ACT) such as Arthemeter 
Lumefantrine (AL). This could be explained by the scores of capacity building and sensitization activities deployed by 
government in collaboration with other organizations among the PMVs in the study area. And this is further buttressed 
by another finding of this study which show that 89.5% of the participants who had undergone training on malaria 
demonstrated awareness of the new malaria treatment policy and preventive measures. This relationship was found to 
be very significant (X2 =17.9034, df = 1, P = 0. 000, OR=8.095, CI =2.8490 – 23.0024). The odd ratio (OR) shows that 
those PMVs who had training on malaria were eight times more likely to be aware of new malaria treatment policy and 
preventive measures than those who didn’t. This finding justifies the continued efforts in making a case for some form 
of capacity building training for PMVs [3, 7, 8, 36]. This training should be made mandatory as a condition for the 
renewal of PMVs’ license. 
5. Conclusion 
It is obvious from the foregoing, that high proportions of PMVs in Gombe metropolis know about presumptive malaria 
diagnosis, prevention and treatment. Notwithstanding, gaps were observed in referral practices and compliance with 
the new malaria treatment policy. However, since this study also established that trainings were more likely to influence 
awareness, more could still be done by all stakeholders in the area of training as well as behavior change communication 
(BCC) activities, and monitoring and supervision of the PMVs. 
This study was not without limitations, the sample size of 109 was imposed by the choice of the study area and the 
limited number of registered PMVs. In addition, the design of the study being cross sectional would mean that 
generalizations from the findings of the study should be done with caution.  
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